STAT3 and rheumatoid arthritis: Our results show that GalXM was able to inhibit phospho-STAT3 activation of RA peripheral blood lymphocytes (PBL) activated by anti-CD3 and anti-CD28 mAbs after 2 and 18 h of treatment (Figure 6A and B).